Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type II pneumocyte | 8 studies | 52% ± 17% | |
| club cell | 6 studies | 74% ± 29% | |
| ciliated cell | 5 studies | 57% ± 32% | |
| type I pneumocyte | 4 studies | 41% ± 16% | |
| basal cell | 3 studies | 33% ± 12% | |
| epithelial cell | 3 studies | 50% ± 32% |
Insufficient scRNA-seq data for expression of SCGB3A2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 6633.49 | 578 / 578 | 68% | 602.61 | 780 / 1155 |
| blood vessel | 75% | 97.81 | 1001 / 1335 | 0% | 0 | 0 / 0 |
| skin | 36% | 7.18 | 660 / 1809 | 1% | 4.51 | 7 / 472 |
| pancreas | 29% | 4.75 | 95 / 328 | 0% | 0 | 0 / 178 |
| heart | 20% | 7.32 | 168 / 861 | 0% | 0 | 0 / 0 |
| stomach | 15% | 7.23 | 54 / 359 | 1% | 0.58 | 3 / 286 |
| thymus | 14% | 3.30 | 89 / 653 | 2% | 0.74 | 10 / 605 |
| peripheral blood | 11% | 7.95 | 103 / 929 | 0% | 0 | 0 / 0 |
| esophagus | 5% | 2.06 | 79 / 1445 | 4% | 1.08 | 8 / 183 |
| breast | 5% | 0.88 | 24 / 459 | 2% | 1.41 | 26 / 1118 |
| bladder | 0% | 0 | 0 / 21 | 7% | 50.45 | 37 / 504 |
| kidney | 2% | 1.55 | 2 / 89 | 4% | 0.57 | 32 / 901 |
| prostate | 5% | 0.78 | 12 / 245 | 0% | 0 | 0 / 502 |
| ovary | 4% | 17.53 | 7 / 180 | 0% | 0 | 0 / 430 |
| spleen | 3% | 0.50 | 7 / 241 | 0% | 0 | 0 / 0 |
| intestine | 2% | 2.27 | 15 / 966 | 1% | 0.18 | 5 / 527 |
| liver | 2% | 0.36 | 5 / 226 | 0% | 0.02 | 1 / 406 |
| uterus | 1% | 0.06 | 1 / 170 | 2% | 0.28 | 7 / 459 |
| brain | 1% | 0.43 | 31 / 2642 | 0% | 0.42 | 3 / 705 |
| adipose | 1% | 0.94 | 17 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 1% | 0.31 | 9 / 803 | 0% | 0 | 0 / 0 |
| adrenal gland | 1% | 0.14 | 2 / 258 | 0% | 0 | 0 / 230 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005615 | Cellular component | extracellular space |
| GO_0071682 | Cellular component | endocytic vesicle lumen |
| Gene name | SCGB3A2 |
| Protein name | Secretoglobin, family 3A, member 2 (Uteroglobin related protein 1) Secretoglobin family 3A member 2 (Pneumo secretory protein 1) (PnSP-1) (Uteroglobin-related protein 1) Secretoglobin family 3A member 2 |
| Synonyms | UNQ566/PRO1128 PNSP1 UGRP1 hCG_1645642 |
| Description | FUNCTION: Secreted cytokine-like protein . Binds to the scavenger receptor MARCO . Can also bind to pathogens including the Gram-positive bacterium L.monocytogenes, the Gram-negative bacterium P.aeruginosa, and yeast . Strongly inhibits phospholipase A2 (PLA2G1B) activity . Seems to have anti-inflammatory effects in respiratory epithelium (By similarity). Also has anti-fibrotic activity in lung . May play a role in fetal lung development and maturation . Promotes branching morphogenesis during early stages of lung development . In the pituitary, may inhibit production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) (By similarity). . |
| Accessions | ENST00000504320.5 ENST00000296694.5 D6RBX5 Q96PL1 Q2L6B3 |
